Is Wall Street Bullish or Bearish on DaVita Stock?

Barchart
在Barchart上打开
Is Wall Street Bullish or Bearish on DaVita Stock?

With a market cap of $10.9 billion, DaVita Inc. (DVA) provides kidney dialysis and related laboratory services for patients with chronic kidney failure, primarily through outpatient centers. It also offers integrated care, clinical research, physician services, and comprehensive kidney care, including home-based and hospital dialysis options.

Shares of the Denver, Colorado-based company have surpassed the broader market over the past 52 weeks. DVA stock has soared 40.8% over this time frame, while the broader S&P 500 Index ($SPX) has gained 10.8%. Moreover, the stock has climbed 53.2% on a YTD basis, compared to SPX's 10.9% rise.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Looking closer, shares of the dialysis specialist have also outpaced the State Street Health Care Select Sector SPDR ETF's (XLV) 23.6% increase over the past 52 weeks.

www.barchart.com

DaVita shares fell 3% despite beating Q3 2026 estimates, as investors focused on rising operating costs and weakening cash generation: patient care costs per treatment increased $8.01 to $280.22, operating cash flow plunged 38% to $519 million and free cash flow dropped 54% to $276 million. Sentiment was further pressured by a $62 million non-cash impairment charge in China, which reduced attributable net income by $27 million, alongside a sequential decline in adjusted operating income to $561 million and adjusted operating margin to 15.7%. 

For the fiscal year ending in December 2026, analysts expect DaVita’s adjusted EPS to grow nearly 36% year-over-year to $14.66. The company's earnings surprise history is promising. It topped the consensus estimates in each of the last four quarters.

Among the eight analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on three “Strong Buy” ratings, four “Holds,” and one “Moderate Sell.” 

www.barchart.com

This configuration has remained unchanged over the past three months.

On Nov. 2, UBS analyst AJ Rice raised its DaVita price target to $287, maintaining a “Buy” rating.

The mean price target of $225.86 represents a 29.8% premium to DVA’s current price levels. The Street-high price target of $287 implies a potential upside of 64.9%.


On the date of publication, Sohini Mondal did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

A Third Affair! Jensen Huang Is Out, and Nvidia Stock Is Still in Trouble. With an IPO Fast Approaching, Anthropic Is Embracing Trump’s Preferred ‘Super Intelligence.’ What That Means for Future ANT Stock Investors. Beaten-Down Hudbay Minerals (HBM) Stock Offers a Compelling Contrarian Narrative 1 Million Reasons to Buy the Dip in Tesla Stock (You Can Thank Terafab)